Present and future treatment strategies for pulmonary arterial hypertension: Focus on phosphodiesterase-5 inhibitors

Treatments in Respiratory Medicine

Volumn 5, Issue 4, 2006, Pages 271-282

  Kane, Laura B ^a   Klings, Elizabeth S ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ANTICOAGULANT AGENT; BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CYCLIC GMP; DILTIAZEM; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; NIFEDIPINE; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTANOID; SILDENAFIL; SITAXSENTAN; TADALAFIL; UNIPROST; VARDENAFIL; VASODILATOR AGENT; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ABSENCE OF SIDE EFFECTS; AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; DIARRHEA; DISEASE CLASSIFICATION; DIZZINESS; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG INHIBITION; DRUG POTENTIATION; ENVIRONMENTAL FACTOR; FLUSHING; HEADACHE; HEART HEMODYNAMICS; HEREDITY; HISTOPATHOLOGY; HUMAN; HYPOTENSION; INJECTION SITE PAIN; LEG PAIN; MOUTH PAIN; NAUSEA; NONHUMAN; NOSE CONGESTION; PATHOGENESIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SIDE EFFECT; SURVIVAL RATE; SYMPTOMATOLOGY; VASODILATATION; VOMITING; ANIMAL; CHEMICALLY INDUCED; HYPERTENSION; HYPERTENSION, PULMONARY;

ANIMALS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; FAMILIAL PRIMARY PULMONARY HYPERTENSION; HUMANS; HYPERTENSION; HYPERTENSION, PULMONARY; PHOSPHODIESTERASE 5 INHIBITORS; PHOSPHODIESTERASE INHIBITORS; VASODILATOR AGENTS;

EID: 33745890620     PISSN: 11763450     EISSN: 11763450     Source Type: Journal    
DOI: 10.2165/00151829-200605040-00005     Document Type: Review

References (76)

1. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987; 107 (2): 216-23
2. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991; 115 (5): 343-9
3. Rich S. Executive summary from the World Symposium on Primary Pulmonary Hypertension; 1998 Sep 6-10; Evian, France. Geneva: World Health Organization, 1998
4. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43 (12 Suppl. S): 5S-12S
5. Barst RJ, Rubin LJ, McGoon MD, et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994; 121 (6): 409-15
6. Fishman AP. Pulmonary circulation. In: Geiger SR, editor. Handbook of physiology: the respiratory system. Baltimore (MD): Williams & Wilkins, 1985: 93
7. Kane LB, Loscalzo J. Pulmonary arterial hypertension. In: Creager MA, Dzau VJ, Loscalzo J, editors. Vascular medicine: a companion to Braunwald's heart disease. 1st ed. Elsevier, 2006: 795-821
8. Hoeper MM, Galie N, Simmonneau G, et al. New treatments for pulmonary arterial hypertension. Am J Respir Crit Care Med 2002; 165: 1209-16
9. Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet 2003; 361 (9368): 1533-44
10. Jeffery TK, Morrell NW. Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. Prog Cardiovasc Dis 2002; 45 (3): 173-202
11. Tuder RM, Cool CD, Yeager M, et al. The pathobiology of pulmonary hypertension; endothelium. Clin Chest Med 2001; 22 (3): 405-18
12. Nichols WC, Koller DL, Slovis B, et al. Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-32. Nat Genet 1997; 15 (3): 277-80
13. Lane KB, Machado RD, Pauciulo MW, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet 2000; 26 (1): 81-4
14. Humbert M, Deng Z, Simonneau G, et al. BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives. Eur Respir J 2002; 20 (3): 518-23
15. Newman JH, Trembath RC, Morse JA, et al. Genetic basis of pulmonary arterial hypertension: current understanding and future directions. J Am Coll Cardiol 2004; 43 (12 Suppl. S): 33S-9S
16. Mandegar M, Fung YCB, Huang W, et al. Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension. Microvasc Res 2004; 68: 75-103
17. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 32: 770-5
18. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334: 296-302
19. Higenbottam T, Wheeldon D, Wells F, et al. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1984; I (8385): 1046-7
20. Friedman R, Mears JG, Barst RJ. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. Circulation 1997; 96: 2782-4
21. Arnal JF, Dinh-Xuan AT, Pueyo M, et al. Endothelium-derived nitric oxide and vascular physiology and pathology. Cell Mol Life Sci 1999; 55 (8-9): 1078-87
22. Sitbon O, Brenot F, Denjean A, et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension: a dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med 1995; 151 (2 Pt 1): 384-9
23. Channick RN, Rubin LJ. Combination therapy for pulmonary hypertension: a glimpse into the future? Crit Care Med 2000; 28 (3): 896-7
24. Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70 (4): 580-7
25. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327 (2): 76-81
26. Adnot S, Raffestin B, Eddahibi S, et al. Loss of endothelium-dependent relaxant activity in the pulmonary circulation of rats exposed to chronic hypoxia. J Clin Invest 1991; 87 (1): 155-62
27. Warren JB, Maltby NH, MacCormack D, et al. Pulmonary endothelium-derived relaxing factor is impaired in hypoxia. Clin Sci (Lond) 1989; 77 (6): 671-6
28. Rubin LJ. Calcium channel blockers in primary pulmonary hypertension. Chest 1985; 88 (4 Suppl.): 257S-60S
29. Rich S, Brundage BH. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation 1987; 76 (1): 135-41
30. Ghofrani HA, Pepke-Zaba J, Barbera JA, et al. Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43 (12 Suppl. S): 68S-72S
31. Klings ES, Farber HW. Current management of primary pulmonary hypertension (review). Drugs 2001; 61: 1945-56
32. Shapiro SM, Oudiz RJ, Cao T, et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 1997; 30 (2): 343-9
33. Badesch DB, McLaughlin VV, Delcroix M, et al. Prostanoid therapy for pulmonary arterial hypertension. J Amer Coll Cardiol 2004; 43: 56S-61S
34. Simmoneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of prostinil, a prostacyclin analog, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 800-4
35. Galie N, Manes A, Branzi A. The new clinical trials on pharmacological treatment in pulmonary arterial hypertension. Eur Respir J 2002; 20 (4): 1037-49
36. Galie N, Humbert M, Vachiery JL, et al. Effects of beraprost sodium, an oral prostacyclin analog, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002; 39 (9): 1496-502
37. Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41 (12): 2119-25
38. Sitbon O, McLaughlin VV, Badesch DB, et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax 2005; 60: 981-3
39. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346 (12): 896-903
40. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 169 (4): 441-7
41. Barst RJ, Rich S, Widlitz A, et al. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest 2002; 121 (6): 1860-8
42. Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006; 47: 2049-56
43. Hampl V, Herget J. Role of nitric oxide in the pathogenesis of chronic pulmonary hypertension. Physiol Rev 2000; 80 (4): 1337-72
44. Corbin JD, Francis SH. Cyclic GMP phosphodiesterase-5: target of sildenafil. J Biol Chem 1999; 274 (20): 13729-32
45. Rosen RC, Kostis JB. Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am J Cardiol 2003; 92 (9A): 9M-18M
46. Ghofrani HA, Roswinckel R, Reichenberger F, et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol 2004; 6: 1488-96
47. Sebkhi A, Strange JW, Phillips SC, et al. Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation 2003; 107 (25): 3230-5
48. Roberts Jr JD, Chiche JD, Weimann J, et al. Nitric oxide inhalation decreases pulmonary artery remodeling in the injured lungs of rat pups. Circ Res 2000; 87 (2): 140-5
49. Schermuly RT, Kreisselmeier KP, Ghofrani HA, et al. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med 2004; 169 (1): 39-45
50. Zhao L, Mason NA, Morrell NW, et al. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 2001; 104 (4): 424-8
51. Leuchte HH, Schwaiblmair M, Baumgartner RA, et al. Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension. Chest 2004; 125 (2): 580-6
52. Michelakis E, Tymchak W, Lien D, et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 2002; 105 (20): 2398-403
53. Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002; 360 (9337): 895-900
54. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2006; 353: 2148-57
55. Mikhail GW, Prasad SK, Li W, et al. Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: acute and mid-term effects. Eur Heart J 2004; 25 (5): 431-6
56. Michelakis ED, Tymchak W, Noga M, et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003; 108 (17): 2066-9
57. Sastry BK, Narasimhan C, Reddy NK, et al. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 2004; 43 (7): 1149-53
58. Ghofrani HA, Rose F, Schermuly RT, et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 2003; 42 (1): 158-64
59. Stiebellehner L, Petkov V, Vonbank K, et al. Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. Chest 2003; 123 (4): 1293-5
60. Beyer S, Speich R, Fischler M, et al. Long-term experience with oral or inhaled vasodilator combination therapy in patients with pulmonary hypertension. Swiss Med Wkly 2006; 136: 114-8
61. Gomberg-Maitland M, McLaughlin V, Gulati M, et al. Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension. Am J Cardiol 2005; 96: 1334-6
62. Humpl T, Reyes JT, Holtby H, et al. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation 2005; 111: 3274-80
63. Madden BP, Allenby M, Loke TK, et al. A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease. Vascul Pharmacol 2006; 44: 372-6
64. Molina J, Lucero E, Luluaga S, et al. Systemic lupus erythematosus- associated pulmonary hypertension: good outcome following sildenafil therapy. Lupus 2003; 12 (4): 321-3
65. Schumacher YO, Zdebik A, Huonker M, et al. Sildenafil in HIV-related pulmonary hypertension. AIDS 2001; 15 (13): 1747-8
66. Wong AR, Rasool AH, Abidin NZ, et al. Sildenafil as treatment for human immunodeficiency virus-related pulmonary hypertension in a child. J Paediatr Child Health 2006; 42: 147-8
67. Aldashev AA, Kojonazarov BK, Amatov TA, et al. Phosphodiesterase type 5 and high altitude pulmonary hypertension. Thorax 2005; 60: 683-7
68. Machado RF, Martyr S, Kato GJ, et al. Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br J Haematol 2005; 130: 445-53
69. Travadi JN, Patole SK. Phosphodiesterase inhibitors for persistent pulmonary hypertension of the newborn: a review. Pediatr Pulmonol 2003; 36 (6): 529-35
70. Lacassie HJ, Germain AM, Valdes G, et al. Management of Eisenmenger syndrome in pregnancy with sildenafil and L-arginine. Obstet Gynecol 2004; 103 (5 Pt 2): 1118-20
71. Ghofrani HA, Schermuly RT, Rose F, et al. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2003; 167 (8): 1139-41
72. Ghofrani HA, Wiedemann R, Rose F, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002; 136 (7): 515-22
73. Bharani A, Mathew V, Sahu A, et al. The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension. Indian Heart J 2003; 55 (1): 55-9
74. Boyce EG, Umland EM. Sildenafil citrate: a therapeutic update. Clin Ther 2001; 23: 2-23
75. Allibhai ZA, Gale JS, Sheidow TS. Central serous chorioretinopathy in a patient taking sildenafil citrate. Ophthalmic Surg Lasers Imaging 2004; 35 (2): 165-7
76. Wilkins MR, Paul GA, Strange JW, et al. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am J Respir Crit Care Med 2005; 171: 1292-7